RxDoctor Payments Data

Michael Wilson, MD

Interventional Cardiology · Portland, ORNPI 1871539973

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,400 of the $6,009 with a category attached, or 73.2%. Abbott accounts for 60.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $3,598 and has fallen 99.4% since, to $22 in 2025.

$6,009in general payments, 2019–2025

Across 51 payments — averaging $117.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medicure Pharma Inc.$1K
  • Johnson & Johnson$430
  • Boston Scientific$202
  • Heartflow, Inc.$145
  • Abiomed$117
  • plus $463 from 11 others

What the payments were for

  • Consulting fees$4,40073%
  • Food & beverage$1,60927%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,009 in reported general payments places this provider in the 55th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$113,378
Medicare patients
593
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$175,666
EntrestoSacubitril/Valsartan21$29,853
Repatha SureclickEvolocumab12$13,421
Repatha SyringeEvolocumab12$10,994
FarxigaDapagliflozin Propanediol11$10,819
Atorvastatin Calcium339$5,578
Metoprolol Succinate274$5,041
Ezetimibe72$3,073
Losartan Potassium170$2,236
Rosuvastatin Calcium143$1,653
Amlodipine Besylate129$1,186
Potassium Chloride50$1,167
Carvedilol104$1,135
Lisinopril105$1,097
ClopidogrelClopidogrel Bisulfate82$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$14$10,81911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →